EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial

Shengyuan Yu iD, Yasuhiko Matsumori iD, Byung-Kun Kim iD, Anna Gryglas-Dworak iD, Gvantsa Giorgadze iD, Patricia Pozo-Rosich iD, Mette Krog Josiassen, Kristina Ranc, Anders Ettrup iD, Aurélia Mittoux, Bjørn Sperling, Takao Takeshima iD

Cephalalgia · 2025

DOI: 10.1177/03331024251386095 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2025. Verfasst von Shengyuan Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine in a predominantly Asian population.

Methods

The multi-regional, randomized, double-blind, placebo-controlled, phase 3 SUNRISE trial randomly assigned adults with chronic migraine to receive eptinezumab 100 mg, 300 mg, or placebo. The primary endpoint was change from baseline in monthly migraine days (MMDs) during Weeks 1–12. Key secondary efficacy endpoints were 50% reduction in MMDs (Weeks 1–12) and 75% reduction in MMDs (Weeks 1–4, Weeks 1–12), and the percentage of participants experiencing migraine on Day 1.

Results

Overall, 978 participants received treatment, including 621 (63.5%) from Asia. Both eptinezumab doses met the primary and all key secondary efficacy endpoints. The mean change from baseline in MMDs (Weeks 1–12) was −7.2 for eptinezumab 100 mg, −7.5 for eptinezumab 300 mg, and −4.8 for placebo. Between-group differences were −2.4 for eptinezumab 100 mg versus placebo ( p < 0.0001) and −2.7 for eptinezumab 300 mg versus placebo ( p < 0.0001). Both eptinezumab doses also demonstrated an odds ratio of >2 versus placebo for all migraine responder rates ( p < 0.0001), and a lower percentage of participants experiencing migraine on Day 1 versus placebo ( p ≤ 0.01). Safety outcomes were similar across treatment groups.

Conclusions

Eptinezumab demonstrated statistically significant greater reductions in MMDs compared with placebo, beginning on Day 1 and sustained through Week 12, with a well-tolerated safety profile consistent with prior clinical trials.

Trial registration

ClinicalTrials.gov (Identifier: NCT04921384); EudraCT (Identifier: 2020-001657-42).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedTreatment OutcomeAsian PeopleChronic DiseaseYoung Adult

Stichwörter der Autor:innen

Chronic migraineeptinezumabmigraine responder ratemigraine treatment in Asiamonthly migraine days

Substanzen

Antibodies, Monoclonal, Humanizedeptinezumab

Autor:innen und Institutionen

  • Department of Neurology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Sendai Headache and Neurology Clinic, Sendai, Japan.
  • Eulji University School of Medicine, Seoul, South Korea.
  • MIGRE Polskie Centrum Leczenia Migreny, Wrocław, Poland.
  • Aversi Clinic LTD, Tbilisi, Georgia.
  • Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Headache and Neurological Pain Research Group, VHIR, Barcelona, Spain.

ORCID-Profile: Shengyuan Yu, Yasuhiko Matsumori, Byung-Kun Kim, Anna Gryglas-Dworak, Gvantsa Giorgadze, Patricia Pozo-Rosich, Anders Ettrup, Takao Takeshima

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Yu, S., Matsumori, Y., Kim, B. K., Gryglas-Dworak, A., Giorgadze, G., Pozo-Rosich, P., Krog Josiassen, M., Ranc, K., Ettrup, A., Mittoux, A., Sperling, B., & Takeshima, T. (2025). Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia. https://doi.org/10.1177/03331024251386095

Vancouver

Yu S, Matsumori Y, Kim BK, Gryglas-Dworak A, Giorgadze G, Pozo-Rosich P, et al. Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia. 2025. doi:10.1177/03331024251386095

BibTeX
@article{Yu2025,
  author = {Yu, Shengyuan and Matsumori, Yasuhiko and Kim, Byung-Kun and Gryglas-Dworak, Anna and Giorgadze, Gvantsa and Pozo-Rosich, Patricia and Krog Josiassen, Mette and Ranc, Kristina and Ettrup, Anders and Mittoux, Aurélia and Sperling, Bjørn and Takeshima, Takao},
  title = {Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251386095}
}
Kostenlos starten →